Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma

Cancer

Volumn 77, Issue 5, 1996, Pages 893-899

  Eton, Omar ^a,d   Talpaz, Moshe ^a   Lee, Kyoo H ^b   Rothberg, Jeanne M ^a   Brell, Joanna M ^c   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Asan Medical Center   (South Korea)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Clinical trial; Cytokine; Human; Interferon alpha; Interleukin 2; Metastatic melanoma

Indexed keywords

INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; APPETITE DISORDER; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; MALE; MELANOMA; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0030024048     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960301)77:5<893::AID-CNCR13>3.0.CO;2-Z     Document Type: Article

References (21)

1. Marincola FM. Interleukin-2. Biologic Therapy of Cancer Updates 1994; 4:1 - 16.
2. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18(5 Suppl 7):83-90.
3. Brunda MJ, Bellantoni D, Sulich V. In Vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987:40:365-71.
4. Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In Vivo anti-tumor activity of multiple injections of recombinant combinations of interleukin-2 alone and in combination with three different types of recombinant interferon, on various synergeneic murine tumors. Cancer Res 1988;48:260-4.
5. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48:5810-17.
6. Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2A in cancer patients: A phase 1 study. J Clin Oncol 1989:7:1726-32.
7. Eton O, Legha SS, Balch CM. Cutaneous melanoma (letter). N Engl J Med 1992:326:345-6.
8. Legha SS, Gianan M, Plager C, Papadopoulos N, Salem P, Benjamin RS. Phase I-II study of IL-2 used as a continuous infusion in patients with metastatic melanoma. Proc Am Ass Cancer Res 1990;31(Abstr 1047):176.
9. Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, et al. Phase II study of recombinant α-Interferon in malignant melanoma. Am J Clin Oncol 1990; 13:472-76.
10. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML. Sznol M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha-2a in patients with advanced melanoma. J Clin Oncol 1993; 10:1969-77.
11. Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer (LAK) cells: Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 1986:46:2784-92.
12. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
13. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994:12:1572-6.
14. Maas RA, Dullens HFJ, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993:36:141-8.
15. Lindemann A, Brossart P, Hoffken K, Hashove M, Voliotis D, Diehl V, et al. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase Ib study. Cancer Immunol Immunother 1993:37:307-15.
16. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Cancer 1993; 72:607-14.
17. Buzaid AC, Legha S. Combination of chemotherapy with Interleukin-2 and Interferon-Alpha for the treatment of advanced melanoma. Semin Oncol 1994:21:23-8.
18. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10:1338-43.
19. Khayar D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993; 11:2173-80.
20. Legha SS, Ring S, Eton O, Plager C, Buzaid A, Papadopoulos N. Durable complete responses in metastatic melanoma treated with biochemotherapy using Cisplatin + Vinblastine + DTIC (CVD) and IL-2 + Interferon-alpha. Proc Am Soc Clin Oncol 1995; 14(Abstr 1305):412.
21. Jain RK. Therapeutic implications of tumor physiology. Curr Opin Oncol 1991;3:1105-08.